ImmunityBio, Inc.
Clinical trials sponsored by ImmunityBio, Inc., explained in plain language.
Immunotherapy biotech developing cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune booster plus standard therapy shows promise for bladder cancer Results expected Sep 2026 (estimated)
- Could an immune booster beat long COVID? small trial begins Results expected Oct 2026 (estimated)
- New bladder cancer cocktail aims to spare patients from surgery Results expected Nov 2026 (estimated)
- Immune cell cocktail takes on Platinum-Resistant ovarian cancer Results expected May 2027 (estimated)
- New immune-boosting combo targets stubborn lymphoma Results expected May 2027 (estimated)
-
New drug takes on tough pancreatic cancer
Disease control CompletedThis study tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to boost the immune system and block a protein that helps tumors grow. The main goals were to check safety and find th…
Phase 1/2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Immune cell therapy shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new immune cell therapy called PD-L1 t-haNK in 16 adults with advanced solid cancers that had spread or could not be removed by surgery. The main goals were to check safety, find the best dose, and see if the treatment could shrink tumors. The ther…
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Healthy donors get drug to supercharge immune cells
Knowledge-focused CompletedThis early study tested a drug called N-803 in 10 healthy volunteers to see if it could help collect and grow more natural killer cells from their blood. The main goal was to check safety and side effects. The study is already complete, but it does not test whether these cells ca…
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC